Mircea Ivan

List of Publications by Year
in descending order

65 papers	8,189 citations	126858 33 h-index	118793 62 g-index
69 all docs	69 docs citations	69 times ranked	10955 citing authors

#	Article	IF	Citations
1	Hypoxia signaling: Challenges and opportunities for cancer therapy. Seminars in Cancer Biology, 2022, 85, 185-195.	4.3	17
2	Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation. Science Advances, 2021, 7, .	4.7	26
3	Ref-1 redox activity alters cancer cell metabolism in pancreatic cancer: exploiting this novel finding as a potential target. Journal of Experimental and Clinical Cancer Research, 2021, 40, 251.	3.5	23
4	Osteocytic miR21 deficiency improves bone strength independent of sex despite having sex divergent effects on osteocyte viability and bone turnover. FEBS Journal, 2020, 287, 941-963.	2.2	10
5	Transcriptomic modifications in developmental cardiopulmonary adaptations to chronic hypoxia using a murine model of simulated high-altitude exposure. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L456-L470.	1.3	4
6	Regulation of cellular sterol homeostasis by the oxygen responsive noncoding RNA lincNORS. Nature Communications, 2020, 11, 4755.	5.8	12
7	HypoxamiR-210 accelerates wound healing in diabetic mice by improving cellular metabolism. Communications Biology, 2020, 3, 768.	2.0	18
8	Glycolysis, via NADHâ€dependent dimerisation of CtBPs, regulates hypoxiaâ€induced expression of CAIX and stemâ€like breast cancer cell survival. FEBS Letters, 2020, 594, 2988-3001.	1.3	5
9	Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers. Breast Cancer Research, 2019, 21, 87.	2.2	26
10	The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress. Oncogene, 2019, 38, 7146-7165.	2.6	75
11	The Many Faces of Long Noncoding RNAs in Cancer. Antioxidants and Redox Signaling, 2018, 29, 922-935.	2.5	45
12	Enteral Arg-Gln Dipeptide Administration Increases Retinal Docosahexaenoic Acid and Neuroprotectin D1 in a Murine Model of Retinopathy of Prematurity. , 2018, 59, 858.		11
13	P38Î±/JNK signaling restrains erythropoiesis by suppressing Ezh2-mediated epigenetic silencing of Bim. Nature Communications, 2018, 9, 3518.	5.8	25
14	Integrative Analysis of AML Cell Response to Cytarabine Reveals Synergistic Opportunities Centered on Cholesterol Metabolism. Blood, 2018, 132, 2631-2631.	0.6	0
15	The EGLN-HIF O 2 -Sensing System: Multiple Inputs and Feedbacks. Molecular Cell, 2017, 66, 772-779.	4.5	192
16	Disruption of the Cx43/miR21 pathway leads to osteocyte apoptosis and increased osteoclastogenesis with aging. Aging Cell, 2017, 16, 551-563.	3.0	110
17	Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica, 2017, 102, e427-e430.	1.7	93
18	The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer. Gynecologic Oncology, 2017, 147, 481-487.	0.6	17

#	Article	IF	Citations
19	Transcriptome analysis of hypoxic cancer cells uncovers intron retention in EIF2B5 as a mechanism to inhibit translation. PLoS Biology, 2017, 15, e2002623.	2.6	41
20	Regulation of HIF1Î± under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models. Molecular Cancer Therapeutics, 2016, 15, 2722-2732.	1.9	91
21	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Molecular Cell, 2016, 61, 520-534.	4.5	142
22	Reduced Chemosensitivity of FLT3/ITD Mutated Cells to Cytarabine and Quizartinib Under Hypoxic Conditions. Blood, 2016, 128, 1579-1579.	0.6	0
23	Enhancing Hematopoietic Stem Cell Transplantation Efficacy by Mitigating Oxygen Shock. Cell, 2015, 161, 1553-1565.	13.5	273
24	Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 (APE1/Ref-1) Redox Function Negatively Regulates NRF2. Journal of Biological Chemistry, 2015, 290, 3057-3068.	1.6	57
25	Knockout of Vdac1 activates hypoxia-inducible factor through reactive oxygen species generation and induces tumor growth by promoting metabolic reprogramming and inflammation. Cancer & Metabolism, 2015, 3, 8.	2.4	36
26	Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer. Journal of Cancer, 2014, 5, 633-645.	1.2	9
27	Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing. Breast Cancer Research and Treatment, 2014, 143, 57-68.	1.1	28
28	miR-210: Fine-Tuning the Hypoxic Response. Advances in Experimental Medicine and Biology, 2014, 772, 205-227.	0.8	101
29	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nature Communications, 2014, 5, 5202.	5.8	151
30	Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nature Communications, 2014, 5, 5203.	5.8	195
31	HypoxamiRs and Cancer: From Biology to Targeted Therapy. Antioxidants and Redox Signaling, 2014, 21, 1220-1238.	2.5	102
32	Ferroxitosis: A cell death from modulation of oxidative phosphorylation and PKM2-dependent glycolysis in melanoma. Oncotarget, 2014, 5, 12694-12703.	0.8	13
33	Mitigation of a Newly Discovered Phenomenon, Extra Physiologic Oxygen Shock/Stress (EPHOSS), Mediated By the Mitochondria Permeability Transition Pore, Greatly Improves Stem Cell Collection and Transplantation. Blood, 2014, 124, 2905-2905.	0.6	4
34	Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts. Journal of Molecular Medicine, 2013, 91, 749-758.	1.7	64
35	Targeting the Insulin Growth Factor and the Vascular Endothelial Growth Factor Pathways in Ovarian Cancer. Molecular Cancer Therapeutics, 2012, 11, 1576-1586.	1.9	29
36	Post-Transcriptional Control of the Hypoxic Response by RNA-Binding Proteins and MicroRNAs. Frontiers in Molecular Neuroscience, 2011, 4, 7.	1.4	98

#	Article	IF	Citations
37	PDGF induced microRNA alterations in cancer cells. Nucleic Acids Research, 2011, 39, 4035-4047.	6.5	40
38	Dihydroceramide-based Response to Hypoxia. Journal of Biological Chemistry, 2011, 286, 38069-38078.	1.6	71
39	Impact of APE1/Ref-1 Redox Inhibition on Pancreatic Tumor Growth. Molecular Cancer Therapeutics, 2011, 10, 1698-1708.	1.9	92
40	microRNA: Emerging therapeutic targets in acute ischemic diseases. , 2010, 125, 92-104.		166
41	MicroRNA-210 Regulates Mitochondrial Free Radical Response to Hypoxia and Krebs Cycle in Cancer Cells by Targeting Iron Sulfur Cluster Protein ISCU. PLoS ONE, 2010, 5, e10345.	1.1	276
42	Blockade of FGF signaling: Therapeutic promise for ovarian cancer. Cancer Biology and Therapy, 2010, 10, 505-508.	1.5	7
43	An Integrated Approach for Experimental Target Identification of Hypoxia-induced miR-210. Journal of Biological Chemistry, 2009, 284, 35134-35143.	1.6	248
44	â€œMicroâ€•management of DNA repair genes by hypoxia. Cell Cycle, 2009, 8, 4009-4010.	1.3	5
45	Emerging Roles of microRNAs in the Molecular Responses to Hypoxia. Current Pharmaceutical Design, 2009, 15, 3861-3866.	0.9	75
46	MicroRNA Regulation of DNA Repair Gene Expression in Hypoxic Stress. Cancer Research, 2009, 69, 1221-1229.	0.4	402
47	Molecular responses to hypoxia: ancient pathways, clinical promises. Journal of Cellular and Molecular Medicine, 2009, 13, 2757-2758.	1.6	0
48	Hypoxia response and microRNAs: no longer two separate worlds. Journal of Cellular and Molecular Medicine, 2008, 12, 1426-1431.	1.6	182
49	<i>â€˜microRNAâ€™ Review Series</i>â€˜The ongoing microRNA revolution and its impact in biology and medicine. Journal of Cellular and Molecular Medicine, 2008, 12, 1425-1425.	1.6	1
50	AMP-activated protein kinase is essential for survival in chronic hypoxia. Biochemical and Biophysical Research Communications, 2008, 370, 230-234.	1.0	22
51	Regulation of microRNA Expression: the Hypoxic Component. Cell Cycle, 2007, 6, 1425-1430.	1.3	132
52	Regulatory mechanisms of microRNAs involvement in cancer. Expert Opinion on Biological Therapy, 2007, 7, 1009-1019.	1.4	150
53	Characterization of Phosphorylation Sites on Tpl2 Using IMAC Enrichment and a Linear Ion Trap Mass Spectrometer. Journal of Proteome Research, 2007, 6, 2269-2276.	1.8	16
54	A MicroRNA Signature of Hypoxia. Molecular and Cellular Biology, 2007, 27, 1859-1867.	1.1	990

#	Article	IF	Citations
55	Regulation of microRNA expression: the hypoxic component. Cell Cycle, 2007, 6, 1426-31.	1.3	86
56	Proteasome-dependent regulation of signal transduction in retinal pigment epithelial cells. Experimental Eye Research, 2006, 83, 1472-1481.	1.2	29
57	Analysis of von Hippelâ€“Lindau Hereditary Cancer Syndrome: Implications of Oxygen Sensing. Methods in Enzymology, 2004, 381, 320-335.	0.4	9
58	Identification of Elongin C and Skp1 Sequences That Determine Cullin Selection. Journal of Biological Chemistry, 2004, 279, 43019-43026.	1.6	10
59	Structure of an HIF-1alpha -pVHL Complex: Hydroxyproline Recognition in Signaling. Science, 2002, 296, 1886-1889.	6.0	679
60	Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 13459-13464.	3.3	520
61	The von Hippelâ€“Lindau tumor suppressor protein. Current Opinion in Genetics and Development, 2001, 11, 27-34.	1.5	209
62	Ubiquitination of hypoxia-inducible factor requires direct binding to the Î²-domain of the von Hippelâ€“Lindau protein. Nature Cell Biology, 2000, 2, 423-427.	4.6	1,423
63	Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene, 1997, 14, 2417-2423.	2.6	144
64	Mitogenic stimulation of normal and oncogene-transformed human thyroid epithelial cells by hepatocyte growth factor. Molecular and Cellular Endocrinology, 1996, 117, 247-251.	1.6	33
65	Spontaneous de-differentiation correlates with extended lifespan in transformed thyroid epithelial cells: An epigenetic mechanism of tumour progression?. , 1996, 67, 563-572.		18